Etiologic heterogeneity between molecular subtypes of prostate cancer

Active Project Grant Awarded Last action

Award ID
R37CA275914
Recipient
Awarding agency
Obligated
$3,967,540

Award facts

Assistance listing
93.393 Cancer Cause and Prevention Research
Completion date 65% complete
Place of performance
Germany

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
This proposed project investigates the hypothesis that risk factors for prostate cancer differ by molecular subtype of the tumor. IT addresses the conundrum that prostate cancer has fewer established risk factors than other cancer types, despite its high incidence and mortality. By credentialing risk factors, this project lays the ground for primary prevention efforts and for mechanistic research. Notably, few studies have investigated etiologic differences based on molecular subtypes of prostate cancer. In this project, we will molecularly profile 3,373 prostate tumors diagnosed among 107,313 men (23% of whom are african-american) who participate in the health professionals follow-up study (hpfs), the physicians' health study (PHS), or the southern community cohort study (sccs) and on whom we have collected decades of prospective risk factor data prior to cancer diagnosis. The project builds on our previous work demonstrating that potential prostate cancer risk factors such as obesity, height, and some inherited genetic variants may specifically be associated with tumors with the common TMPRSS2:ERG fusion. To assess the most common molecular subtypes with different mechanisms of carcinogenesis, we will apply cutting-edge, in-situ pathology methods for (1) gene fusions from the ETS family (TMPRSS2:ERG, ETV1, ETV4, ETV5), (2) loss of the tumor suppressor pten, and (3) gain of the oncogene MYC. In aim 1, we will generate population-based data on the prevalence of the common tumor alterations by age at diagnosis and assess the CO-occurrence of molecular phenotypes at the cellular level with integrated single-cell data. In aim 2, we will assess risk factors for molecular subtypes of prostate cancer. We will characterize which molecular subtypes are associated with non-modifiable risk factors (family history, attained height, and inherited risk as measured by the polygenic risk score for prostate cancer), modifiable risk factors with substantial prior evidence (adult-age adiposity and smoking), and novel risk factors for specific subtypes (physical activity and insulinemic dietary patterns). In aim 3, we will tailor the cbioportal, the most widely used cancer genomics portal, for accessible data-sharing in molecular cancer epidemiology. The impact of this project will be the generation of the first population-based, age-specific prevalence data on molecular subtypes and their CO-occurrence; the connection between etiology and molecular heterogeneity; and the availability of high-quality original data from decades of follow-up for the research community. Importantly, a nuanced understanding of the etiology of prostate cancer is indispensable to reducing its mortality burden through primary prevention, as IT has been for other tumor entities. Credentialing any additional modifiable risk factor is poised to have a significant impact, given the quickly rising burden of prostate cancer with the aging of the global population.

Transactions

Action Obligated Date
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $639,285
Amendment $0
Amendment Institute transfer of grant R37CA275914: etiologic heterogeneity between molecular subtypes of prostate cancer $639,285
Amendment $0
Amendment $639,285
Amendment $639,285
Amendment $0
Amendment $654,340
Original award $756,060
Show all 16

Subawards

Subrecipient Amount Awarded
President And Fellows Of Harvard College The investigators at the Harvard TH Chan School of Public Health have expertise in cancer epidemiology, biomarkers, biostatistical methods, and prostate… $396,736
Vanderbilt University Medical Center For the proposed project, Dr. Shrubsole will assume primary responsibility for activities in the following areas: • Coordinate and oversee the SCCS data… $176,821
The Johns Hopkins University Dr. Lotan’s group will oversee postdoctoral pathology fellow for the centralized grading and staging of the ~700 new prostate tumors collected for TMA… $516,394

Quick answers

Who received award R37CA275914?

R37CA275914 was awarded to Leibniz-Institut FÜR Präventionsforschung UND Epidemiologie - Bips GMBH by National Cancer Institute (National Institutes of Health) on August 1, 2023.

How much is award R37CA275914 worth?

$3,967,540 has been obligated on R37CA275914.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login